Orexigen Therapeutics Research Coverage Started at Credit Suisse (OREX)
Analysts at Credit Suisse began coverage on shares of Orexigen Therapeutics (NASDAQ:OREX) in a research report issued to clients and investors on Thursday. The firm set an “outperform” rating and a $10.00 price target on the stock. Credit Suisse’s target price indicates a potential upside of 71.82% from the stock’s previous close.
Separately, analysts at Zacks reiterated a “neutral” rating on shares of Orexigen Therapeutics in a research note on Wednesday, July 16th. They now have a $5.50 price target on the stock. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Orexigen Therapeutics currently has a consensus rating of “Buy” and an average price target of $8.92.
Orexigen Therapeutics (NASDAQ:OREX) traded up 3.61% on Thursday, hitting $6.02. 1,354,350 shares of the company’s stock traded hands. Orexigen Therapeutics has a one year low of $4.60 and a one year high of $7.82. The stock has a 50-day moving average of $5.43 and a 200-day moving average of $5.9. The company’s market cap is $737.7 million.
Orexigen Therapeutics (NASDAQ:OREX) last released its earnings data on Thursday, August 7th. The company reported ($0.21) earnings per share for the quarter, meeting the analysts’ consensus estimate of ($0.21). Analysts expect that Orexigen Therapeutics will post $-0.21 EPS for the current fiscal year.
Orexigen Therapeutics, Inc develops drug treatments for obesity and related disorders. Orexigen Therapeutics, Inc develops and commercializes combinations of currently available drugs that are designed to achieve and sustain weight loss by enhancing satiety, diminishing appetite, improving energy expenditure and minimizing the body’s efforts to compensate for weight loss.
Receive News & Ratings for Orexigen Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orexigen Therapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.